Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Omeros Corporation

Market Cap 744M 648M 598M 562M 1.05B 70.12B 1.06B 7.11B 2.76B 34.56B 2.79B 2.73B 120B P/E 2026 *
31.2x
P/E 2027 * -52.3x
Enterprise Value 744M 648M 598M 562M 1.05B 70.12B 1.06B 7.11B 2.76B 34.56B 2.79B 2.73B 120B EV / Sales 2026 *
11x
EV / Sales 2027 * 5.19x
Free-Float
96.44%
Yield 2026 *
-
Yield 2027 * -
1 day+6.64%
1 week+0.98%
Current month-6.88%
1 month-12.14%
3 months-6.12%
6 months+12.23%
Current year-40.15%
1 week 8.82
Extreme 8.82
10.42
1 month 6.7
Extreme 6.7023
12.55
Current year 6.7
Extreme 6.7023
17.63
1 year 2.95
Extreme 2.95
17.65
3 years 0.92
Extreme 0.92
17.65
5 years 0.92
Extreme 0.92
17.65
10 years 0.92
Extreme 0.92
27.09
Manager TitleAgeSince
Chief Executive Officer 67 16/06/1994
Director of Finance/CFO 62 30/06/2024
Chief Tech/Sci/R&D Officer 70 01/11/2019
Director TitleAgeSince
Chairman 67 16/06/1994
Director/Board Member 86 01/01/1995
Director/Board Member 72 01/01/1995
Date Insider Type Main position Quantity % Market Cap.
22/05Fiscal year

Director

22,500 0.0313%
18/02Fiscal year

Chief Executive Officer

1,157,678 1.6328%
12/01Sell

Chief Financial Officer

120,000 0.1693%
Change 5-day change 1-year change 3-year change Capi.($)
+6.64%+0.98%+219.25%+72.19% 698M
-2.23%-1.65%+61.34%+109.10% 56.24B
+4.60%+5.82%+56.35%+43.04% 43.76B
-1.44%+1.51%-12.94%-19.24% 23.32B
-2.69%-0.95%-3.68%+379.00% 21.34B
+3.22%+2.94%+24.02%-35.05% 15.75B
-0.67%+0.65%+14.86%-39.22% 15.6B
-1.01%-2.97%+27.42%+171.92% 13.18B
+3.07%+5.43%+21.37% - 12.01B
+4.95%+13.49%+121.11%+249.05% 11.87B
Average +1.44%+2.01%+52.91%+103.42% 21.38B
Weighted average by Cap. +0.52%+1.53%+39.08%+97.98%

Financials

2026 *2027 *
Net sales 67.83M 59.1M 54.48M 51.25M 95.87M 6.39B 96.55M 648M 252M 3.15B 255M 249M 10.92B 143M 125M 115M 108M 202M 13.5B 204M 1.37B 532M 6.65B 538M 526M 23.06B
Net income 21.23M 18.5M 17.05M 16.04M 30.01M 2B 30.22M 203M 78.8M 986M 79.7M 77.99M 3.42B -21.9M -19.08M -17.59M -16.55M -30.95M -2.06B -31.17M -209M -81.27M -1.02B -82.2M -80.44M -3.53B
Net Debt - -
Logo Omeros Corporation
Omeros Corporation is a clinical-stage biopharmaceutical company. The Company focuses on discovering, developing, and commercializing first-in-class small-molecule and protein therapeutics for both large-market and orphan indications, with a particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. Its clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program. Its commercial product, YARTEMLEA, is the approved inhibitor of the lectin pathway of complement. YARTEMLEA is used for the treatment of TA-TMA in adults and in children ages two years and older. YARTEMLEA selectively inhibits MASP-2, blocking pathway activation while preserving classical and alternative complement pathway functions.
Employees
175
Date Price Change Volume
18/06/26 10.28 $ +6.64% 2,634,400
17/06/26 9.640 $ +1.69% 1,417,148
16/06/26 9.480 $ +1.61% 2,608,247
15/06/26 9.330 $ +6.81% 1,960,054
12/06/26 8.735 $ -14.19% 7,784,719
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
10.28USD
Average target price
40.00USD
Spread / Average Target
+289.11%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OMER Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!